Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
| Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
| Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
| Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete | ||
| Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Saphris | Asenapine | Schizophrenia | Do not list | Complete | ||
| Saphris | Asenapine | Bipolar I disorder | List with clinical criteria and/or conditions | Complete | ||
| Strensiq | Asfotase alfa | Hypophosphatasia, pediatric-onset | List with criteria/condition | Complete | ||
| Sunvepra | Asunaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Translarna | ataluren | Cancelled |
Last Updated : April 27, 2024